NCT00937625已完成1 期
T-cell Based Immunotherapy for Treatment of Patients With Disseminated Melanoma.
Inge Marie Svane2 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2009年6月最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 31
- 试验地点
- 2
- 主要终点
- toxicity
研究概览
简要总结
The aim of this study is to investigate the toxicity and clinical response of therapy with tumor infiltrating lymphocytes as treatment for advanced melanoma.
Patient will receive a single treatment consisting of conditioning chemotherapy for seven days (cyclophosphamide for two days and fludarabine for five days), intravenous infusion of high number of in vitro expanded tumor infiltrating lymphocytes followed by two weeks with daily low-dose interleukine-2. Patients will be evaluated for toxicity, tumor response, and immune response.
After the first 6 patients the treatment with IL-2 has been changed to include higher doses of IL-2 (see intervention)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histological proven skin derived progressive metastatic or locally advanced malignant melanoma. Further inclusion criteria: Performance Status 0 to 1, surgical available metastasis, at least one measurable lesion, acceptable CBC and blood chemistry results. Acceptable organ functions.
排除标准
- •Patients with a history of any other malignancies less than five years ago. Brain metastases. Other significant illness including severe allergy, asthma, DM, angina pectoris, congestive heart failure, chronic infections, or active autoimmune disease. Treatment with immune suppressive drugs, experimental drugs, or antineoplastic drugs.
结局指标
主要结局
toxicity
时间窗: week 0 to 20
次要结局
- tumor response(week 8 and every 3rd week until progression)
- immune response(week 0 to 20)
研究者
Inge Marie Svane
Professor
Herlev Hospital
研究点 (2)
Loading locations...
相似试验
撤回
1 期
T-cell Based Immunotherapy for Head and Neck CancerHead and Neck CancerSquamous Cell CarcinomaNCT00937300Inge Marie Svane
招募中
1 期
Immunotherapy for the Treatment of Advanced Solid TumorRecurrence TumorMetastatic CancerSolid TumorNCT03658785Tongji Hospital40
终止
1 期
A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg)Metastatic MelanomaNCT01082887Nantes University Hospital18
招募中
早期 1 期
TCR-T Cells in the Treatment of Advanced Pancreatic CancerPancreatic CancerNCT06054984Ruijin Hospital18
已完成
2 期
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell LiposarcomaNeoplasmsNCT06703346USWM CT, LLC82